Review Polyglutamine Diseases: Where does Toxicity Come from? What is Toxicity? Where are We Going?

Although the genetic basis of polyglutamine diseases has been recognized for 20 years, their molecular basis is still unclear. We have no therapeutic strategies for these intractable neurodegenerative disorders. To adequately treat patients, we must clarify the molecular basis of polyglutamine diseases. Three main issues address their molecular pathogenesis: whether the specific struc-ture of expanded polyglutamine diseases results in cellular toxicity; what type of dysfunction causes them; and how the toxic struc-ture causes dysfunction, that is, the link between structure and dysfunction. For structures, expanded polyglutamine proteins undergo transformation from monomers to oligomers and inclusions. One can hypothesize that one of these structures might cause the polyglutamine disease. Although the expanded polyglutamine protein is toxic, it does not explain the selective vulner-ability of specific neurons in each polyglutamine disease. The normal function of each protein, including protein–protein interaction and modification, might also be crucial for pathogenesis. For dysfunction, various molecular mechanisms have been proposed, including dysregulation of transcription, impairment of the ubiquitin–proteasome system, mitochondrial dysfunction, dysregulation of intracellular Ca21 homeostasis, impairment of axonal transport and genotoxic stress. These hypotheses might correlate with each other. In addition, the disease pathogenesis of might not be exclusive to one particular structure or dysfunction. To develop a thera-peutic strategy for patients with polyglutamine disease, identifying the most toxic structure and the earliest event in the pathogen